Journey Medical
DERM

$5.10

0.39%

Market Cap: $106M

About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Employees: 58

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

99% more capital invested

Capital invested by funds: $6.68M [Q1] → $13.3M (+$6.63M) [Q2]

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

6% more funds holding

Funds holding: 33 [Q1] → 35 (+2) [Q2]

2.32% more ownership

Funds ownership: 14.53% [Q1] → 16.85% (+2.32%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

76%

upside

Avg. target

$9.67

90%

upside

High target

$11

116%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Lake Street Thomas Flaten 57% 1-year accuracy 4 / 7 met price target	76%upside $9	Buy Initiated	6 Sept 2024
Rodman & Renshaw	76%upside $9	Buy Initiated	22 Aug 2024
Roth MKM Jason Wittes 61% 1-year accuracy 11 / 18 met price target	116%upside $11	Buy Reinstated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City.

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference.

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript

Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors.

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript

Journey Medical Corporation (NASDAQ:DERM ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim Chief Financial Officer Dr. Srinivas Sidgiddi - Vice President, Research and Development Ramsey Allous - General Counsel and Corporate Secretary Conference Call Participants Scott Henry - Alliance Global Partner Kalpit - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

See News Rankings